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ABBREVIATIONS 
AIH: autoimmune hepatitis 
ALK: alkaline phosphatase 
ALT: alanine aminotransferase 
AMA: anti-mitochondrial antibodies 	  
ANCA: anti-neutrophil cytoplasmic antibodies 
ANNA: anti-neutrophil nucleus antibodies 	  
AST: aspartate aminotransferase 
CA 19-9: carbohydrate antigen 19-9 
CT: computed tomography  
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MRI: magnetic resonance imaging	  
PSC: primary sclerosing cholangitis 
SMA: anti-smooth muscle antibodies 
LT: liver transplantation	  
UDCA: ursodeoxycholic acid 
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ABSTRACT 
BACKGROUND AND AIMS 
The natural history of paediatric onset PSC and PSC/AIH overlap syndrome is poorly known. 
Thus, this study was aimed at evaluating the clinical course and outcome of patients with a 
paediatric onset of disease. 
MATERIALS AND METHODS 
Between December 1993 and December 2011, thirty-five patients (median age at diagnosis 15 
years), with confirmed PSC by cholangiography (ERC) and PSC/AIH by cholangiography 
and the modified score for AIH, were traced at Helsinki University Central Hospital. Clinical 
characteristics (symptoms and signs, associated diseases), diagnostic procedures (lab tests, 
liver biopsy, ERC) and long-term follow-up (mortality, liver transplantation, recurrence of the 
disease in the graft, malignancy) were reassessed until December 2013. 
RESULTS   
The original diagnosis was PSC in 22 children (63%) and PSC/AIH overlap syndrome in 13 
(37%). At diagnosis most of the children had an insidious onset and most an associated IBD, 
being UC the most common form. Still, 4/35 (11%) had cirrhosis. Endoscopic retrograde 
cholangiography during follow-up was available for all of the patients and images showed a 
progression of intra-hepatic disease in 13/28 (46.4%) (p=0.0102). In the last follow-up 
(median 8 years), all patients were alive. Twenty-eight out of 35 patients (80%) and 13/35 
patients (40%) were taken UDCA and immunosuppressive therapy, respectively; 3 patients 
were without treatment. Transaminases and GGT improved significantly. Four patients (11%) 
had undergone liver transplantation (after a median 7.5 years) and one was listed; and 
additional patient was transplanted because of Budd-Chiari syndrome. No difference in graft 
free survival was seen between patients with PSC and PSC/AIH. Three patients (two with 
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PSC and one with PSC/AIH overlap syndrome) presented with cirrhosis. No malignancy 
occurred. 
CONCLUSION    
The clinical outcome of primary sclerosing cholangitis and overlap syndrome seems 
comparable including their progression to cirrhosis and requirement for liver transplantation. 
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INTRODUCTION 
 
PRIMARY SCLEROSING CHOLANGITIS 
 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by 
inflammation and progressive fibrosis of intra- and extra-hepatic bile ducts (1). In children 
PSC is often associated with features of autoimmune hepatitis (AIH); this peculiar form of 
PSC is referred as PSC/AIH overlap syndrome (2). Paediatric onset PSC is a rare condition, 
while the clinical course and prognosis of the disease is still unclear. To our knowledge, so far 
only four papers with a long follow-up (one from Europe and three from U.S.A.) have been 
reported the clinical course and prognosis of paediatric onset PSC (3-6) and new studies on 
this topic are warranted (7).  
This thesis was conducted thanks to the collaboration between “Meilahti Hospital - Helsinki 
University” (Helsinki, Finland) and “Fondazione IRCCS “Ca’ Granda” Ospedale Maggiore 
Policlinico – University of Milan” (Milan, Italy). Firstly, the introduction reports an overview 
of PSC, regarding particularly epidemiology, aetio-pathogenesis, diagnosis and therapy of the 
disease and highlighting the main differences between children and adults. Secondly, the 
study presents the long-term clinical course and prognosis of a paediatric onset PSC and 
PSC/AIH overlap syndrome in a cohort of patients in Finland.    
 
DEFINITIONS 
PSC is a chronic cholestatic liver disease characterized by inflammation and fibrosis of intra- 
and extra-hepatic biliary ducts, leading to focal or multiple bile ducts strictures (8, 9). The 
disease was first descripted by Hofmman in 1867. No medical treatment is currently available 
and the disease usually progresses to cirrhosis, liver failure and need of liver transplantation 
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(LT). In children, adolescent and young adults, PSC is often associated with clinical, 
biochemical and histologic features of AIH and this clinical variant is referred as 
autoimmune sclerosing cholangitis or PSC/AIH overlap syndrome (2). Small duct PSC 
refers to a clinical variant of PSC characterized by similar cholestatic and histologic features 
of PSC but with a normal cholangiographic picture because the disease involves the smallest 
bile ducts (10).  
The term secondary sclerosing cholangitis refers to a group of diseases causing patchy 
inflammation, fibrosis and strictures of the intra- and/or extra-hepatic biliary system and 
leading cholestasis (11). Immunoglobulin G4 (IgG4) associated cholangitis may represent a 
distinct entity characterized by the same cholangiographic features of PSC but with important 
differences such as high levels of IgG4 in serum, association with other fibrotic diseases (e.g., 
autoimmune pancreatitis) and good response to steroid therapy (12).   
 
EPIDEMIOLOGY 
Incidence and prevalence. The epidemiology of PSC is not well-characterized as few 
population-based studies have been published on this topic and only one focused on paediatric 
population (5). This study was conducted in the State of Utah (U.S.A.) in 29 children with 
PSC and 12 children with PSC/AIH, reporting an incidence and prevalence of PSC as 
0.2/100.000 inhabitants/year and 1.5/100.000 inhabitants, respectively and of PSC/AIH as 
0.1/100.000 inhabitants/year and 0.6 /100.000 inhabitants, respectively (5). Another 
population-based study (13) was conducted in the State of Alberta (Canada) including 46 
adults and only three children. The reported incidence rate for PSC in children was 
0.23/100.000 inhabitants per year; no data regarding prevalence has been shown. No other 
studies have investigated the prevalence of PSC and the incidence and prevalence of 
PSC/AIH overlap syndrome in paediatric population. 
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Recently, one systematic review and meta-analysis conducted in Canada (14) and one 
systematic review conducted in Netherland (15) presented a comprehensive overview of the 
epidemiology of PSC. These systematic reviews have been included studies conducted mostly 
in adults. The first systematic review, including six population-based studies (two from North 
America and four from Europe) (13, 16-19) reported an incidence rate of 1.0/100.000 
inhabitants per year, a risk two-fold greater in males and a median age at the diagnosis of 41 
years; PSC incidence rate seemed to increase over time. The second systematic review 
included eleven studies of which only four (13, 16, 19, 20) were considered of good quality 
according to the definition of study population, case-finding method and case-ascertainment 
criteria. The incidence and prevalence rate for PSC ranged from 0 to 1.3/100.000 inhabitants 
per year and 0 - 16.2/100.000 inhabitants, respectively. PSC incidence showed an increasing 
in temporal trend (15).  
Inflammatory bowel disease (IBD) - PSC. PSC is strongly associated with IBD in children 
as well as in adults. In children, IBD is reported in about 80% of cases (mostly ulcerative 
colitis) (6). IBD seems to be less common in children affected by PSC/AIH (2). Conversely, 
in a population based-study PSC occurred in 9.9% and 0.6% of children with ulcerative colitis 
and Crohn’s disease, respectively and PSC/AIH in 2.3% and 0.4% of children with ulcerative 
colitis and Crohn’s disease, respectively (5).  
In adults, IBD is reported up to 80% of PSC patients in northern countries (i.e., North 
America and Scandinavia) compared to 20-54% of those living in South Europe and Asia (21-
24); ulcerative colitis accounts for the majority (80%) of cases. The prevalence of PSC in IBD 
adult patients is 2-7.5% in ulcerative colitis and 1.4-3.4% in patients with Crohn’s disease 
(25, 26).  
IBD-PSC shows a unique phenotype (27). The inflammation is usually mild (28) and the 
distribution is typically pancolonic, with rectal sparing, with frequent backwash ileitis (27). 
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PSC-IBD patients less likely undergo colectomy but they have more frequently pouchitis after 
surgery compared to patients with only IBD (27, 29). 
 
AETIOPATHOGENESIS 
The aetiopathogenesis of PSC and PSC/AIH is unknown. Whether or not PSC/AIH is a 
distinct disease entity or a result of progression from PSC to AIH or vice versa is still debated 
(30, 31). The higher incidence of these diseases in northern countries  (i.e., North America 
and North Europe) as well as in patients affected by IBD suggests an interaction between 
unidentified environmental risk factors and a complex genetic background.  
Environmental risk factors.  Studies on environmental risk factors in paediatric onset PSC 
and PSC/AIH overlap syndrome are still lacking in the literature. So far, five studies on 
environmental risk factors in adults have been published. A suggested protective role of 
smoking (32-34) and of tonsillectomy (35) is reported. Appendectomy is not a protective 
factor for PSC (33, 35) as it is for ulcerative colitis. Finally, coffee consumption and females 
hormones might have a protective role against PSC (34). 
Genetic factors. First-degree relatives of patients with PSC have a 100-fold increased risk of 
developing disease, suggesting a strong genetic component (36) that seems to include both 
non-HLA (37, 38) and HLA genes on chromosome 6 (39). Genes may be involved in 
cholangiocyte biology, inflammation pathway, fibrosis and carcinogenesis. The largest 
genetic study conducted recently on PSC patients showed that half of the PSC genes are not 
associated with IBD but they overlap with other autoimmune diseases such as psoriasis, 
rheumatoid arthritis, coeliac disease and diabetes I (40).   
Others factors. Another hypothesis involves immunologic mechanisms. Inflamed gut (IBD) 
may release TNFalfa that in turn increases methylamine in portal blood that via VAP1 activity 
might induce MADCAM1, an endothelial adhesion molecule usually absent from liver 
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vascular bed. In turn, this aberrant MADCAM1 may recruit lymphocytes in the liver (hepatic 
homing) (41, 42). Another hypothesis involves the loss of hydrogencarbonate layer of normal 
biliary epithelium, which usually protects against the biliary acid (bile duct toxicity) (43). A 
change in gut microbiota may promote penetration of microbes or toxins from colon to the 
liver via-portal flow. A specific genetic background (i.e., FUT2) may be associated with 
bacterial or viral infection (44). 
 
DIAGNOSIS 
Symptoms and signs. Most of the children with PSC and PSC/AIH are referred for 
nonspecific complaints such as fatigue, abdominal pain, isolated splenomegaly/hepatomegaly 
and jaundice (45). Itching is rare (less then 20% of cases) (4, 6). At the disease onset about 
19-29% of children is asymptomatic (4, 6), presenting severe fibrosis or cirrhosis on liver 
histology (4). By contrast, in adults asymptomatic patients are over 40% (46). Itching is more 
common (30%) and other symptoms are fatigue, abdominal pain, hepatomegaly/splenomegaly  
(46, 47). Cirrhosis and its complications at PSC onset are more rare in adults (46, 47).   
Laboratory tests. Children with PSC or PSC/AIH usually present elevation of transaminase 
(alanine aminotransferase - ALT and aspartate aminotransferase - AST) and gamma 
glutamyltranspeptidase (GGT) (4, 6). Transaminases might be higher in children affected by 
PSC/AIH (5, 48). Total bilirubin and alkaline phosphatase (ALP) might be within normal 
range in the majority of the patients (4-6); hepatic iso-enzyme of ALP would be a more 
accurate marker, as the normal range of ALP is large due to the effect of bone maturation in 
children. By contrast, elevation of ALP is the hallmark of PSC in adults; transaminases are 
usually 2-3 times upper normal limit (46, 47). Also in adult total bilirubin level is within 
normal range in most of the patients (46, 47).  
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Serology. A large number of autoantibodies have been associated with PSC without any 
difference between paediatric and adult patients. Anti-Neutrophil Cytoplasmic Antibodies 
(ANCA) were detected in PSC patients by Snook et al in 1989 (49). The peri-nuclear pattern 
(pANCA) is the most common being reported in 26-94% of the patients (50, 51). However, 
pANCA present an atypical pattern in PSC as the main antigen is located in the nucleus rather 
than in cytoplasm and thus they are referred as Anti-Neutrophil Nucleus Antibodies (ANNA) 
(51). pANCA have a low specificity for PSC being present also in AIH, IBD and other 
autoimmune diseases (51) and they are not accurate in differentiating between PSC and 
PSC/AIH in children (4-6). Currently, pANCA should not be used in the diagnosis and 
follow-up of patients affected by PSC (9). Anti-Nuclear Antibodies (ANA) and Anti-Smooth 
Muscle Antibodies (SMA) are the hallmarks of AIH type I both in children and in adults (3, 
52). However, ANA and SMA are also detected in 8-77% and 0-83% of the PSC patients, 
respectively (53) and in more than 90% of children with PSC/AIH often in association with 
an increase level of Immunoglobulin G (IgG)/gamma-globulins (2, 4-6). Therefore, ANA and 
SMA should not be checked routinely in patients with PSC but only in those with a suspicious 
of overlap with AIH (9). Anti-Mitochondrial Antibodies (AMA) used in the diagnosis of 
primary biliary cirrhosis and anti-Liver-Kidney Microsomal antibodies type 1 (anti-LKM1) 
used in the diagnosis of AIH type II have never been detected in patients with PSC or 
PSC/AIH (53).     
Liver Biopsy. Liver biopsy should not be performed routinely in the presence of an abnormal 
cholangiogram because it doesn’t add useful diagnostic information  and the rate of false 
negatives is high (54). However, in some Centres liver biopsy is performed routinely in 
children to exclude PSC/AIH overlap syndrome. Peri-ductal concentric fibrosis (“onion-
skin”), the classic histopathologic finding of PSC, is uncommon (about 13% of the patients) 
(54). In two studies on paediatric onset PSC liver biopsy was performed in almost all the 
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patients at the time of diagnosis, showing features highly suggestive of PSC in the majority of 
them (4, 6). However, liver biopsy is recommended only in suspected small duct PSC or 
overlap syndrome (8, 9).   
Imaging. Traditionally, endoscopic retrograde cholangiography (ERC) has been considered 
the gold standard for the diagnosis of PSC but its role is now debated (8, 9). The 
cholangiographic pattern of PSC includes short and annular strictures, alternating with normal 
or slightly dilated segments (“beaded appearance”) diffusely involving both the intra- and 
extra-hepatic bile ducts; about 25% of patients may have only intra-hepatic disease whereas 
isolated extra-hepatic disease is extremely rare (< 5%) (55). The same findings are reported in 
children (4, 6, 45). However, ERC needs hospitalization and the technique is associated with 
complications also in PSC patients with an overall rate of 10% (56, 57). The two main ERC-
related complications reported in PSC patients are acute pancreatitis (57) and acute 
cholangitis (56). Magnetic resonance cholangio-pancreatography (MRCP) has been suggested 
as an alternative option to ERC because of cost-effectiveness (58), absence of ionising 
radiations and complications. Still, a recent meta-analysis on diagnostic performance of 
MRCP for diagnosis of PSC, including 6 studies (59-63), reported a sensitivity of 0.86 and a 
specificity of 0.94 with a positive likelihood ratio of 15.3 and a negative likelihood ratio of 
0.15 (64). For the considerations mentioned-above, MRCP should be used in the diagnostic 
workup of autoimmune liver diseases in children (7, 61, 65). However, the studies on MRCP 
performance in diagnosing PSC have many limitations: the study designs, the absence of clear 
gold standard, the low number of patients included and the lack of stratification according to 
disease severity. Moreover, MRCP was not so accurate as ERC in detection of early changes 
of PSC in some studies (59, 66). Therefore, ERC should have still a pivotal role in PSC 
management both in diagnosis (i.e., monitoring of biliary dysplasia with brush cytology and 
DNA analysis, see below) and in therapeutic approach (i.e., biliary dilatation and stenting).       
	   15	  
 
DIFFERENTIAL DIAGNOSIS 
PSC should be differentiated from: 
Small duct PSC. It is a clinical variant of PSC, diagnosed in a patient with normal 
cholangiography but with similar cholestatic and histological features of PSC (67, 68). In one 
paediatric series small duct PSC was reported in about 35% of the patients (4). Recently, one 
study (10) investigated the natural history and long-term prognosis of a cohort of small duct 
PSC patients (n=83) compared with classic PSC; this cohort includes three different series of 
small duct PSC patients published in 2002 (69-71). This variant is more prevalent in male 
(male:female=2:1) and the median age at diagnosis is 38 years (IQR: 28-50) like in classic 
PSC. About 80% of patients have IBD (mostly UC) like in classic PSC. Interestingly, about 
30% of the patients’ progresses to large duct PSC in a medium time of 7.4 years (5.1-14); 
nevertheless patients may progress to end-stage liver disease and need of LT without 
developing necessarily large duct PSC. LT free survival is longer in small duct PSC patients 
(13 years) than in classic PSC (10 years) and the disease might recur in the allograft. Finally, 
patients affected by small duct PSC seem to have a better long-term prognosis (mortality was 
13% compared to 30% in large duct PSC patients); neither cholangio-carcinoma nor 
hepatocellular-carcinoma is reported. Ursodeoxycholic acid (UDCA) does not seem to be an 
effective treatment.  
Immunoglobulin G4 associated cholangitis. It is a steroid responsive inflammatory biliary 
disease, frequently involving extra-hepatic biliary tree and often associated with other fibrotic 
disorders (e.g., autoimmune pancreatitis) (12, 72). It is characterized by elevation of IgG4 in 
serum and by infiltration of IgG4 positive plasma cells in the organs involved (12). Very 
limited data are available on the disease but it seems that it does not occur in children (4, 6).   
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Secondary sclerosing cholangitis. Before a diagnosis of PSC is given, secondary causes of 
sclerosing cholangitis should be properly excluded. The main causes are: biliary stones, 
Caroli’s disease, biliary surgery, cholangiocarcinoma, chronic biliary infections, drugs, and 
ischemia. The diagnostic criteria are described in a recent review and are not reported in this 
dissertation (11).  
 
MALIGNANCY 
The increased risk for gastrointestinal malignancy in patients with PSC is well established. In 
a Swedish cohort of 604 PSC patients the standard incidence ratio for all gastrointestinal 
cancers combined was 28.6 (95%CI: 22.4-36.1); still the standard incidence ratio was 160.6 
(95%CI: 120.3-210.1) for hepatobiliary cancer (i.e., cholangiocarcinoma, hepatocellular 
carcinoma and gallbladder carcinoma), 10.3 (95%CI: 5.3-18.1) for colorectal cancer and 14.3 
(95%CI: 4.7-33.4) for pancreatic cancer (73).  
Cholangiocarcinoma. Cholangiocarcinoma did not occur in two series of PSC children after 
a median/mean follow-up of 6.9/6.5 years (4, 6). In a population-based study in children, 
cholangiocarcinoma occurred in 2/29 PSC patients (6.9%) and both of them died (5). In 
population-based studies in adults the cumulative incidence of cholangiocarcinoma has been 
reported between 7-14% (46, 47, 73-76). Up to 50% of cholangiocarcinoma are diagnosed 
within the first year of diagnosis of PSC (73, 74) and thereafter the yearly incidence is 0.5-
1.5% (73, 75, 76). The diagnosis of cholangiocarcinoma in PSC patients is based on tumour 
markers in serum, imaging modalities, biliary brush cytology and analysis of DNA but in 
37% of patients it is diagnosed during intended liver transplantation or autopsy (74).  In the 
Mayo Clinic study carbohydrate antigen 19-9 (CA19-9) had an optimal cut-off of 20 U/mL 
(normal value < 40 U/mL), which yielded a positive predictive value of 23% and a negative 
predictive value of 96% for the diagnosis of cholangiocarcinoma (76)
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showing a role of CA19-9 as screening test in asymptomatic PSC patients, although a 
screening strategy combining serum CA19-9 and imaging study has been suggested (8, 76). In 
the Mayo Clinic study US, CT and MRI had a poor positive predictive value (48%, 38% and 
40%, respectively) and a high negative predictive value (95%, 95%, 91%, respectively) for 
cholangiocarcinoma; the positive predictive value improved when overall finding was 
considered (i.e., well-defined mass lesion) (76). Brush cytology has a sensitivity of only 8% 
but an excellent specificity (80-90%) for detection of low- and high-grade dysplasia (76); 
however this method needs to be validated in the future and ERCP with brush cytology 
should not be considered as surveillance for cholangiocarcinoma (8, 9). Finally, in the Mayo 
Clinic study digital imaging analysis (DIA) and fluorescence in situ hybridisation (FISH) had 
an high negative predictive value (87% and 95%, respectively) and a low positive predictive 
value (50% and 52%, respectively) for chromosomal abnormalities (and these techniques may 
increase the diagnostic performance of brush cytology (76).  
Colorectal carcinoma.  Colorectal carcinoma did not occur in three series of PSC children 
after a long follow-up (2, 4, 6). However, PSC has been reported as a risk factor for IBD-
related colorectal cancer (77). A meta-analysis, including eleven studies in adults, concluded 
that the risk of dysplasia/colorectal cancer in PSC-UC patients is increased then UC patients 
alone with an OR of 4.7 (95%CI: 3.6-6.4) (78). A high risk was reported also for CD (79). 
The tumour seems to develop more often on the right side of the colon although it can also be 
located on the left side (80-82). The mechanism by which PSC could be associated with an 
increased risk of colorectal cancer in IBD is still unclear. PSC-IBD patients usually have 
pancolitis with a mild disease activity, which could be involved in cancer development (27). 
Colorectal cancer can also occur after LT (83-85). Finally, a chemoprevention effect of 
UDCA has been suggested but the evidence of its efficacy is still limited. Surveillance 
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colonoscopy should be performed at one-year to 2-year from the time of diagnosis of PSC; 
this interval could be longer in children (8, 9).    
Others tumours: PSC patients have a high risk of gallbladder cancer (86); this risk seems to 
be absent in children (4-6). However, yearly US of gallbladder is recommended and 
cholecystectomy should be performed in presence of polyps (8, 9).  
PSC patients with cirrhosis may develop hepatocellular carcinoma and they should be 
managed according to general guidelines (8, 9).    
 
TREATMENT 
UDCA. In adults the European Association for the Study of the Liver reports “The limited 
data base does not yet allow a specific recommendation for the general use of UDCA in 
PSC”, whereas the American Association for the Study of Liver Diseases recommends 
“against the use of UDCA as medical therapy” (8, 9). Initial studies demonstrated that UDCA 
improves only biochemical parameters and histologic features (87-89); a double blind 
randomised placebo-controlled study conducted in 105 patients for a median follow-up of 2.2 
years showed that 13-15 mg/kg of UDCA per day improves biochemical parameters but no 
survival (90). Subsequently, studies in adults showed that increased doses of UDCA (17-23 
mg/kg per day) improve biochemical parameters but not significant end-points like cirrhosis, 
need of liver transplantation and death (91, 92). Recently, a long-term double blind 
randomised placebo-controlled study conducted in 150 adult patients with PSC was 
terminated after 6 years because of high rate of adverse events (i.e., cirrhosis, 
cholangiocarcinoma, liver transplantation and death) in UDCA group (93); interestingly 
adverse events are higher in patients with early stage disease and normal biochemical 
parameters (94). Finally, UDCA does not seem to prevent cholangiocarcinoma and colorectal 
cancer as previously reported (95-97). Only few retrospective series conducted in paediatric 
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patients reported that also in children UDCA seems to improve clinical and biochemical 
features of the patients without having an impact on survival (4, 6, 48).    
Immunosuppression. Prednisolone, budesonide, azathioprine, cyclosporine, methotrexate, 
mycophenolate and tacrolimus have not effect on PSC (8, 9). However, corticosteroids and 
azathioprine may have a role in children with PSC/AIH overlap syndrome (2), although the 
real impact on survival is still lacking (4, 6) as immunosuppressive therapy reduces the 
inflammation component (i.e., interface hepatitis) without any improvement on biliary 
changes.  
Endoscopic treatment. Endoscopic treatment is needed in patients with a symptomatic 
dominant stricture (i.e., in presence of jaundice, itching, right upper quadrant abdominal pain, 
cholangitis, worsening of biochemical indices) (8, 9). A dominant stricture is defined as a 
stenosis with a diameter of  < 1.5 mm in the common bile duct or of < 1 mm in the hepatic 
duct (98). A dominant stricture occurs in about 50% of PSC patients during the follow-up (47, 
98); the exact prevalence in children with PSC is unknown but probably is low. The 
appearance of a dominant stricture always raises the suspicion of cholangiocarcinoma and 
brush cytology and/or biopsy should always be obtained.  
So far, no randomized controlled trial on the efficacy and optimal method of endoscopic 
therapy in the treatment of dominant stricture in PSC has been published. However, two 
retrospective studies suggested that endoscopic therapy improves survival in symptomatic 
PSC patients and it is associated with a low complication rate (99, 100). Sphincterotomy is 
used to facilitate balloon dilatation and/or stenting and it is rarely used alone (100, 101). 
Balloon dilatation has been shown to be effective both with and without stenting (102). 
However, biliary stenting seems to be associated with more complications and a longest 
hospitalization than balloon dilatation only (101-104). A multicentre, prospective, randomized 
interventional trial aim at comparing the efficacy of a single session balloon dilatation and a 
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short-term stenting is now ongoing in the International PSC Study Group 
(http://www.ipscsg.org/). Percutaneous approach is effective as endoscopic ones but it is 
associated with increased morbidity (102, 103). Antibiotic prophylaxis before endoscopic 
and/or percutaneous approach (e.g., ciprofloxacine) is mandatory. Surgery (i.e., cholangio-
enterostomy or resection of the extrahepatic biliary stricuture and Roux Y 
hepaticojejunostomy) is rarely used and it should be proposed to patients without cirrhosis 
when endoscopic and percutaneous approach is failed. 
Liver Transplantation. LT is the only curative therapy for PSC. Indications for LT did not 
differ from those of other forms of chronic liver diseases. Model for End-stage Liver Disease 
score is used for organ allocation in United States and in other countries. Additional 
indications for LT are intractable pruritus, recurrent bacterial cholangitis and repeatedly 
confirmed high-grade biliary dysplasia (105). Cholangiocarcinoma is usually a 
contraindication for LT. Five-year survival after LT is approximately 85% in adults (106, 
107) and it could be even higher (90-100%) in children (2, 4, 6). Disease recurrence may 
occur both in children (2-54%) (2, 4, 6, 108) and in adults (in about 20-25% of cases) (106, 
109, 110). Risk factors for recurrence are male sex, presence of an intact colon, active IBD 
and history of acute cellular rejection (111, 112); younger age (< 30 years), cytomegalovirus 
infection within three months after LT and graft from related donors are also reported in 
children (108). The impact of PSC recurrence on survival remains still controversial (109, 
112, 113).  
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AIM 
The aim of the present study was to report a long-term clinical course and outcome of a 
cohort of patients with a paediatric onset of PSC and PSC/AIH in order to contribute to a 
better definition of the natural history and management of these conditions. 
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MATERIAL AND METHODS 
Study design 
Retrospective observational cohort study. 
Study area, period and population 
Between December 1993 and December 2011, 41 patients with a suspected paediatric onset 
PSC and PSC/AIH were consecutively referred to the HUCH, a tertiary referral centre in 
Finland (5.4 million inhabitants), serving a defined population of about 1 500 000 inhabitants 
and covering approximately 30% of the total child population in the country (www.stat.fi). 
Most of the endoscopic retrograde cholangiography investigations in paediatric and adult PSC 
patients are performed at HUCH.  
Case-ascertainment  
One gastroenterologist and one paediatrician reviewed all the patients’ medical records to 
ensure the correct diagnosis. Diagnosis of PSC was based on: (i) typical imaging features of 
PSC in ERC, and eventually (ii) presence of cholestasis (i.e., elevated gamma GGT and/or 
ALP), and (iii) liver histology suggestive or typical for PSC. Patients affected by secondary 
sclerosing cholangitis, as well as by other liver diseases (i.e., viral and/or metabolic), were 
excluded. Patients fulfilling the diagnostic criteria for both PSC and AIH were considered as 
having PSC/AIH. To this respect, the simplified diagnostic criteria for AIH, recently validated 
in children (114), were retrospectively applied to the patients to ensure the diagnosis of 
PSC/AIH.  
Data regarding clinical history (i.e., symptoms and signs at the time of diagnosis and in the 
last follow-up, associated IBD, associated autoimmune diseases) were collected. Symptoms 
and signs of the disease onset were grouped with the following criteria: asymptomatic (e.g. 
elevation of liver enzymes discovered by chance), acute hepatitis (e.g., malaise, fever, nausea 
and vomiting, diarrhoea, abdominal pain followed by jaundice and cholestasis), complications 
	   23	  
of portal hypertension (e.g., encephalopathy, ascites, oesophageal varices, splenomegaly) and 
acute liver failure. Laboratory tests at the time of diagnosis and during the last follow-up were 
collected. Biochemical parameters included total bilirubin, ALT, AST, GGT, ALP, albumin, 
and international normalized ratio (INR). Serologic parameters were also collected, including 
immunoglobulin M (IgM), IgG, ANA, SMA, AMA, anti-LKM1 and pANCA. Medical 
treatment during the follow-up time (i.e., UDCA and immunosuppressive) was detected. 
Finally, need and timing of LT, as well as occurrence of complications associated with PSC 
(i.e., cholangiocarcinoma, colorectal carcinoma) were registered.  
Liver biopsies were re-reviewed by an experienced pathologist blinded to the patients’ clinical 
history. The pathologist looked for the following features: number of portal spaces included in 
the samples, peri-cholangiolar fibrosis, fibrosis (staging), inflammation (grading), portal 
inflammation, interface inflammation, lobular inflammation, rosette formation, plasma cells, 
eosinophil, granuloma, cholangitis, peri-cholangitis, necrosis, macro- and micro-steatosis, 
cupper (when available), diastase PAS positive globules (when available), hepatocellular 
cytokeratin 7 positivity (when available), loss of bile ducts, acute cholestasis, and PSC 
alteration (0-3; 0=no features of PSC, 1=unspecific features of PSC, 2=features suggestive of 
PSC and 3=diagnostic features of PSC). Some of these features were detected in order to 
exclude other liver diseases.  
In our hospital, all the patients with a suspicion of PSC undergo ERC. PSC changes detected 
by cholangiography are scored with Amsterdam PSC score (115), modified regarding 
intrahepatic scoring at our Clinic (Table 1). During ERC, brush cytology is performed from 
both intra- and extra-hepatic bile ducts and an additional sample for DNA flow-cytometria is 
collected only when the biliary changes are moderate or severe according to the modified 
Amsterdam Score (score > 2). Depending on the modified Amsterdam PSC score and 
presence of dysplasia and/or aneuploidy, the patient is followed with ERC and abdominal CT 
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or MRI. In case of severe dysplasia repeatedly confirmed on brush cytology, the patient is 
considered as a candidate for LT. All ERC images were re-reviewed independently by two 
experienced gastroenterologists. The cholangiographic findings including focal strictures, 
focal dilatations, and any alterations of the bile ducts wall involving both intra- and/or extra-
hepatic bile ducts were re-scored by using the modified Amsterdam PSC score. All the 
therapeutic procedures performed during ERC (i.e., sphincterotomy, biliary dilatation, and/or 
stenting) were also recorded.  
For the study purpose, follow-up was considered to start when the patient was referred to 
HUCH for the suspicion of PSC (liver biopsy and/or ERC) and ended at the time of the last 
consultation at HUCH (outpatient clinic and/or liver biopsy and/or ERC by the end of 
December 2013).  
Statistical analysis  
Data are presented as median and range when continuous. Since the normal range of ALP 
varies according to the age of the paediatric patient, ALP was considered a categorical 
variable (i.e. normal/elevated).  
PSC and PSC/AIH groups were compared with the patients assigned to their original 
diagnosis and with the patients assigned to their reviewed diagnosis. Categorical variables 
were compared between and within groups by using Fisher´s Exact Test (small number of 
subjects). Continuous variables were compared between and within groups by using Mann-
Whitney Test and Wilcoxon Test, respectively. Kaplan-Meyer method was performed for 
survival analysis; the end-points were LT and/or listing for LT for PSC and/or PSC/AIH. A p 
value < 0.05 was considered statistically significant.   
Ethical consideration 
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The study protocol has been approved by the Ethics Committees of HUCH (Diary number: 
64/13/03/03/12). 
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RESULTS 
Patient population 
In the final analysis 35 patients (median age at diagnosis 15 years) were included (Table 2). 
Five patients (median age 14 years: range 7-17; male: 1) were excluded because the diagnosis 
has been changed during the follow-up: choledochal cyst in two, hepatitis related to 
azathioprine in one, acute hepatitis of unknown origin in one and autoimmune hepatitis in 
one. One patient (10-year-old boy) with a diagnosis of PSC was excluded because he was lost 
to follow-up.   
The original diagnosis was PSC in 22 patients (62.8%) and PSC/AIH in 13 (37.1%) patients. 
All the cholangiography images at the time of diagnosis were available and review confirmed 
the diagnosis of PSC in all 35 patients. The simplified score for AIH could retrospectively be 
calculated in 25 patients (71.4%): 18 patients had their diagnosis confirmed (PSC n=11 and 
PSC/AIH n=7), whereas in 6 patients the diagnosis was changed on review from PSC into 
PSC/AIH (probable n= 1 and definite n=5), and in one from PSC/AIH into PSC. In the 
remaining 10 patients, the simplified score for AIH reassessment could not be calculated 
because of missing laboratory tests and/or liver biopsy at the time of diagnosis.  
Clinical presentation at the time of diagnosis 
Background characteristics and clinical presentation of children at PSC and PSC/AIH onset 
are shown in Table 2. PSC and PSC/AIH patients did not differ regarding sex or age. 
Asymptomatic elevation of liver enzymes was the most common presentation in both 
diagnostic groups. None of the patients presented with acute liver failure. At the time of 
diagnosis, 4/35 patients (11.4%) – 2/22 with PSC (9.1%) and 2/13 with PSC/AIH (15.8%) 
(p=0.62) - were cirrhotic; in one patient the diagnosis was based on clinical and radiologic 
findings whereas in three on histologic picture. Three of cirrhotic patients had signs of portal 
hypertension (hepato-splenomegaly). According to the reviewed diagnosis 1/12 patient with 
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PSC (8.3%) and 3/13 with PSC/AIH (23.1%) were cirrhotic (p=0.59). Patients with PSC most 
likely had an associated IBD (p=0.006) and UC was the most prevalent form without being 
significant (p=0.06) (Table 2); the difference was not evident in patients with reassessed 
diagnosis (p=0.32 and p=0.07, respectively). Other autoimmune diseases were associated in 3 
patients with PSC (diabetes type I, nephritis and leuko-trombocytopenia, respectively) and in 
3 patients with PSC/AIH (systemic lupus erythematosus, diabetes type I and rheumatoid 
arthritis, respectively) (p=0.65) and no significant group difference was seen upon 
reassessment (p=1.0). 
ERC findings at the time of diagnosis and in the last follow-up 
At the time of diagnosis, ten patients (28.6%) had intra- and extra-hepatic disease, 25 patients 
(71.4%) had only intra-hepatic disease; isolated extra-hepatic disease was not present in any 
patients. Short papillotomy was performed in 15 (42%) procedures. Dilatation of bile ducts 
was performed in 9 patients (26%): 3 in patients with intra-hepatic and 6 in patients with 
extra-hepatic disease. Biliary stenting was not performed on any of the patients. 
During follow-up, a repeated ERC was available in 28/35 patients (80%). The median number 
of ERC per patient performed during the follow-up period was 3 (range 1-8). The modified 
Amsterdam score showed a progression of intra-hepatic disease in 13/28 patients (46.4%; 
p=0.0102) and of extra-hepatic disease in 3/28 patients (10.7%; p=0.8516).  
Liver histology at the time of diagnosis 
Liver biopsy was performed at the time of diagnosis in 33/35 patients (94.3%). For re-
viewing, 25/33 (75.7%) samples were available. Of these, the diagnostic liver biopsy could 
not be re-evaluated in one PSC patient because of the absence of portal spaces in the sample, 
nevertheless another biopsy performed during the follow-up was reviewed and it showed PSC 
changes without characteristics of AIH (e.g., interface hepatitis). Histologic features on liver 
biopsy of children at PSC or PSC/AIH onset after the re-assessment of the diagnosis are 
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shown in Table 3. Interestingly, 17/35 (48%) of the patients had no features or unspecific 
features of PSC. Still, 7/35 (20%) had severe fibrosis or cirrhosis at the disease onset. 
Laboratory tests at the time of diagnosis and in the last follow-up 
The laboratory tests of children at PSC and PSC/AIH onset are shown in Table 4. ALT and/or 
AST were elevated in 31/34 (91.2%) and in 27/34 (79.4%) of the tested patients, and levels 
were similar between the groups. Bilirubin was normal in 25/34 (73.5%) and the level was 
higher in the PSC/AIH group (p=0.0430), although the median was within the reference 
range. GGT was elevated in 30/34 (88.2%) and no difference between groups was found. 
ALP was normal in 12/34 (35.3%) of the patients. Albumin was lower in the PSC/AIH group 
(p=0.0110), whereas INR was within the normal range for all patients. Regarding serological 
parameters, IgG was elevated in 24/33 (72.7%) and the level was higher in the PSC/AIH 
group (p=0.0352); by contrast IgM level was within normal range in all of the tested patients. 
ANA and/or SMA titre was positive more frequently in the PSC/AIH group (p=0.0248), 
whereas the rate of pANCA positive patients did not differ between groups. Finally, AMA 
and anti-LKM1 were negative in all tested patients (n=34 and n=27, respectively).  
When laboratory tests at the time of diagnosis were compared in patients according to their 
reassessed diagnosis (PSC=12 and PSC/AIH=13), the IgG level and ANA/SMA positivity 
were still statistically higher in the PSC/AIH group (p=0.0001 and p=<0.0001) and no other 
differences between groups were found.  
The level of transaminases and GGT improved significantly during the follow-up period both 
in PSC and in PSC/AIH groups (Figure 1 and Figure 2).  
Clinical course and prognosis 
Long-term clinical outcome is shown in Figure 3. The median follow-up was 8 years (range: 
2-20). At the last follow-up all the patients were alive. No cholangiocarcinoma or colorectal 
cancer was diagnosed during the follow-up period. At the end of the study, 30 patients 
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(85.7%) were still non-transplanted but three (10%) had cirrhosis, of which two had already at 
the time of diagnosis, one PSC patient was listed for LT, and one with PSC/AIH and 
progression of PSC underwent evaluation for LT. Twenty-eight out of 35 patients (80%) were 
on UDCA (at daily dosage of 450 to 1500 mg). Twelve patients (40%) were treated with 
immunosuppressant therapy: 3 PSC patients (2 with an associated IBD) and 9 PSC/AIH 
patients (6 with an associated IBD). Three PSC patients (one of them reassigned to the 
PSC/AIH) were without treatment. 
During the follow-up, 4 patients were transplanted for PSC or PSC/AIH (11.4%) - 2 PSC and 
2 PSC/AIH (1 PSC and 3 PSC/AIH after the reassessment) - after a median time of 7.5 years 
(range: 3-12) from diagnosis. Indications for LT were one each cirrhosis and refractory 
jaundice; cirrhosis (already present at the time of diagnosis) associated with repeatedly 
documented severe biliary dysplasia and aneuploidy; repeatedly documented severe biliary 
dysplasia and aneuploidy; and constant elevation of Ca19-9 and Ca12-5. One 9 year-old girl 
with PSC and cirrhosis at the time of diagnosis was transplanted one year later because of 
Budd-Chiari syndrome and thus she was not included in the survival analysis as it was not 
possible to establish whether or not cirrhosis was related to PSC. Kaplan-Meier curves of 
patient graft free survival for the PSC and the PSC/AIH patients are shown in Figure 4. No 
difference between the two groups of patients was seen (p=0.9553), even when patients were 
reassigned according to their re-reviewed diagnosis (p=0.3716). At the end of follow-up, all 
transplanted patients were alive and no patient had recurrence of disease in the graft.  
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DISCUSSION 
Statement of principal findings. To our knowledge, this is the longest follow-up study in 
Europe investigating the clinical course and prognosis of paediatric onset PSC and PSC/AIH 
documented systematically with ERC imaging with brush cytology. To this respect, a better 
definition of the natural history of these diseases is pivotal as their prevalence has markedly 
increase during the last years, especially in Scandinavia, in line with the increasing incidence 
of IBD (116). The main findings of this study on the clinical course of the PSC in paediatric 
patients are: 1) the PSC/AIH is easily associated in children with PSC; 2) the concomitant 
AIH did not seem to affect the clinical course of PSC; 3) both the diseases may have a high 
risk for cirrhosis already at the time of diagnosis implicating the importance of more early 
diagnosis of the disease; and 4) both the diseases seem to have a good prognosis.  
PSC/AIH overlap syndrome. In this series, PSC/AIH occurred in 37.1% of the patients and the 
rate increased up to 52%, when the diagnosis was reassessed (in those with available data) by 
using the simplified score for AIH, recently validated in children (114). This rate is in line 
with 50% reported by Gregorio et al (2) and lower compared with 25-35% found in other 
series (4, 6). This finding, however, confirms that PSC presents frequently with autoimmune 
features in children (2). Still, the high number of patients with PSC/AIH misdiagnosed at the 
time of diagnosis suggests a certain lack of awareness among clinicians and pathologists 
about these liver diseases (e.g., in the interpretation of liver biopsy) and it highlights the 
importance to address patients with a suspicion of PSC and PSC/AIH to a centre experienced 
in their management. The simplified score for AIH was demonstrated to be an easy and 
accurate method for the diagnosis of AIH both in adults (117) and in children (114). 
However, the score has been validated in a small sample of paediatric patients recruited from 
a single tertiary care hospital (114), which might lead to an overestimation of the performance 
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of the test. New studies are warranted in the future to confirm the accuracy and reliability of 
this score in children. 
Presentation at the time of diagnosis. Children with PSC had a more frequently associated 
IBD, whereas those with PSC/AIH presented higher IgG level or circulating ANA/SMA. 
Otherwise, no other difference in clinical presentation at the time of diagnosis was found. 
Both of the diseases affected mostly boys with an onset in the second decade of life, as 
previously reported in the literature (4, 6, 45). Similar to two other large series (4, 6), most of 
the children (74%) had an associated IBD, UC being the most common (68%). Still, children 
with PSC suffered from IBD more frequently compared with their peers affected by PSC/AIH 
(91% vs. 46%, respectively). Recently, Deneau et al reported a comparable result in a 
paediatric cohort of PSC and PSC/AIH patients in Utah (U.S.A.), although the rate of IBD in 
the PSC/AIH group was as high as 75% (5). Gregorio et al found that 44% of PSC/AIH 
children had an IBD (2). So far, all studies have shown that PSC and IBD do not have a 
common genetic background (37, 39) supporting the paradigm of a unique phenotype PSC-
IBD (27). Whether PSC/AIH-IBD and PSC-IBD share a common genetic link is difficult to 
ascertain because of the rarity of these conditions.  
Because of the retrospective design of the study, we grouped the patients’ symptoms and 
signs into four classes in order to better define the clinical presentation of PSC and PSC/AIH 
in children. The asymptomatic elevation of liver enzymes was the most common presentation 
(62.8%), as previously reported in the literature (45). Transaminases and GGT were elevated 
in most of the children and their level did not differ between the PSC and PSC/AIH group. 
The result was confirmed after the reassignment of the patients according to their re-reviewed 
diagnosis. Adults with PSC usually present cholestasis because the inflammation 
predominantly involves bile ducts (47, 48). In children, the inflammation seems to also affect 
the hepatocellular compartment. A higher level of transaminases and/or GGT in children with 
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PSC/AIH, compared to those with PSC, was reported in two studies (4, 5) but not in others 
(6). Interestingly, 35% of the children with PSC presented normal total ALP or bilirubin 
(73%) supporting the idea that ALP and bilirubin are unreliable markers of PSC. In adults, 
bilirubin is normal in up to 70% of the patients at the time of diagnosis (47). ALP was in 
normal range in 19% and 25% of PSC children in two other large series (4, 6) in contrast to 
adults that comprised 3% of the patients (118). In children, the hepatic isoenzyme of ALP 
might be a more accurate marker of PSC as bone maturation contributes to the total level of 
ALP (6). IgG level was higher and circulating ANA/SMA more common among PSC/AIH 
children confirming the florid autoimmune pattern seen in this disease subgroup of patients 
(2, 4-6). ANCA was not a specific marker to distinguish PSC and PSC/AIH.  
In the current series, most of the patients (71.4%) had only intra-hepatic involvement and no 
patients presented isolated extra-hepatic disease. Feldstein et al found only intra-hepatic PSC 
in about 40% and only extra-hepatic in 2% of the children (6). Isolated extra-hepatic 
involvement is also less common in adults (55). In this study all the patients have been 
followed-up with ERC, which at our hospital is still considered the gold standard for the 
diagnosis of PSC. In the last years, MRI was reported as an accurate, safe, and cost-effective 
tool in the diagnosis of PSC although false negative and/or false positive cases do occur (64). 
ERC is an invasive procedure associated with complications such as pancreatitis, bleeding, 
perforation, and cholangitis (119-121), especially after papillotomy (122). However, the 
complications rate might be low in a high volume centre (123). In HUCH, over 1200 ERCP 
per year are performed and in PSC patients only a short papillotomy is usually done. The 
complication rate in PSC patients is low. In recent series of our unit consisting of 441 patients 
with PSC undergoing ERC, 7% had pancreatitis, of which two patients required 
hospitalization for two weeks and six patients developed cholangitis (1.6%) (57). 
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Clinical course and prognosis. All the patients were still alive in the last follow-up. Although 
in one study, the treatment with UDCA and immunosuppressant did not seem to have an 
impact on survival in patients with a paediatric onset PSC and PSC/AIH (6), most of our 
children received UDCA and most of those with PSC/AIH also immunosuppression.  
Cirrhosis was present in two children each with PSC (9%) and with PSC/AIH (16%) at the 
time of diagnosis; two of them were transplanted. Miloh et al reported that 9% of the PSC 
children had cirrhosis at disease onset, and 56% of those affected by PSC/AIH had severe 
fibrosis or cirrhosis (4). Similarly, Feldstein et al reported severe fibrosis and cirrhosis in 54% 
of the PSC children at the time of diagnosis (6). Overall, LT was performed in approximately 
11% of the patients after a median time of 7.5 years from the diagnosis of the liver disease. 
Survival free of LT was similar between PSC and PSC/AIH patients. Interestingly, in this 
study the rate of transplanted patients was lower compared to other studies with a similar 
follow-up, also showing a shorter time free of LT (4-6). In two single-centre series (4, 6) 
children with PSC or PSC/AIH required LT in 19% and 21% of cases after a mean and 
median time of 7 and 12.5 years, respectively. In a recent multi-centre study (5), 17% of the 
PSC-PSC/AIH children underwent LT. So far, none of our patients have showed recurrence 
of PSC and or AIH in the graft, although reported both in adults (106) and in children (6). 
We did not identify cases of cholangiocarcinoma after a median follow-up of 8 years. In 
adults with PSC the lifetime risk of cholangiocarcinoma has been reported as high as 5-10% 
(73). In two single-centre paediatric studies cholangiocarcinoma was not identified after a 
mean and median follow-up of 6.6 and 6.3 years, respectively (4, 6). Conversely, in one 
population-based study cholangiocarcinoma was reported in approximately 7% of paediatric 
cases (5). We speculate that the follow-up protocol performed in our centre - which is based 
on endoscopic (i.e., ERC), radiologic (i.e., MRI/CT) and pathologic (i.e., cytology and flow-
cytometry) findings – might help to select patients for optimal timing for LT and to prevent 
	   34	  
complications. Interestingly, recurrent severe biliary dysplasia with aneuploidy on cytology 
samples and persistent elevation of neoplastic markers in one of each patient indicated LT, 
which probably have prevented the occurrence of malignancy. However, American (8) and 
European (9) guidelines recommend that ERC with brush cytology and/or fluorescence in situ 
hybridization (FISH) should not be considered as an evidence-based screening method for 
cholangiocarcinoma in PSC patients. Recently, Barr Fritcher et al reported that FISH might 
detect patients with polysomic cells in brushing samples before other techniques, identifying 
those having a higher risk of cholangiocarcinoma (124). New prospective multi-centre long-
follow-up studies are warranted in order to establish the best diagnostic approach in these 
patients. 
Strengths and weakness of this study. This study may be affected by a detection bias (i.e., the 
number of patients missed) as well as by a referral bias (i.e., diseases severity). We consider, 
however, the impact of these biases to be low as in Finland most paediatric patients with a 
suspicion of PSC are referred from all over the country to HUCH for the diagnosis and the 
follow-up. The strength of this study is the documentation of PSC diagnosis with ERC done 
by balloon occlusion technique to ensure visualisation of early intrahepatic changes. 
Moreover, the patient population was followed up by ERC and brush cytology. Conversely, 
the diagnosis of overlap syndrome could be reassessed in not more than 75% of the patients 
because of retrospective design of this study (i.e., missing samples) leading to a minor 
misclassification bias. However, the statistical analysis, comparing the two diagnostic groups, 
was performed by assigning the patients both to their original diagnosis and to their re-
reviewed diagnosis. Finally, this study presents the longest follow-up of paediatric PSC 
patients reported in Europe. 
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CONCLUSIONS 
In conclusion, the differential diagnosis between PSC and PSC/AIH might be challenging and 
PSC/AIH may be easily detected in PSC children. PSC and PSC/AIH may present with 
cirrhosis already at the time of diagnosis highlighting the importance of an earlier diagnosis of 
the disease.  The overlap with AIH did not seem to affect the clinical course of PSC, but a 
strict follow-up in a centre with experience in the management of these diseases may have an 
impact on the prognosis.  
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CURRENT AND FUTURE STUDIES 
A new prospective multicentre study on clinical course and prognosis of PSC in children is 
warranted in order to confirm the results of these few single centre series presented in the 
literature.  
Moreover, many points remain challenging in paediatric onset PSC. Thus, I participated to the 
following studies during my working time in Finland: 
1) one study aimed at investigating environmental risk factors in paediatric onset PSC and 
PSC/AIH overlap syndrome. The study is concluded and it shows that having a cat or having 
a dog in childhood may be a risk factor for the development of PSC and PSC/AIH overlap 
syndrome. This result may guide future preventive interventions for these diseases. The paper 
is under evaluation for publication.  
2) one study including both adults and children aimed at evaluating the significance of early 
ERC and brush cytology to screen for PSC and biliary dysplasia in a large unselected PSC 
patient population coming to their first ERCP, to find factors associated with the development 
of biliary neoplasia and to study the relevance of brush cytology regarding the outcome. The 
study is concluded and showed that about 7% of the patients have high-grade dysplasia or 
cholangiocarcinoma at the time of their first ERC. Advanced PSC and elevated AST, ALT 
and GGT correlate to the development of biliary neoplasia. ERC with brush cytology may 
help to identify patients who need follow-up and eventually liver transplantation. The paper is 
under evaluation for publication.   
3) one study aimed at reporting the role of MRCP in the diagnosis and follow-up of PSC 
patients comparing with ERC. This study will include both children and adults. The protocol 
is ready and it will start in January 2015. 
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TABLES AND FIGURES 
Table 1. Modified Amsterdam PSC Score for primary sclerosing cholangitis 
Score Intra-hepatic system 
0 No visible abnormalities 
1 Ductural irregularities 
2 Multiple calibre change; minimal dilatation 
3 Multiple strictures; saccular dilations and decreased arborisation 
4 Only central branches filled despite adequate filling pressure; severe pruning 
 Extra-hepatic system 
0 No visible abnormalities 
1 Slight irregularities of duct contour; no strictures 
2 Segmental strictures 
3 Strictures of almost entire length of the duct 
4 Extremely irregular margins; diverticulum-like outpunching 
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Table 2. Background characteristics and clinical presentation at the time of diagnosis of 
PSC or PSC/AIH in paediatric patients 
 PSC 
(n=22) 
PSC/AIH 
(n=13) 
p 
Median age and range (years)         15 (5-19) 15 (8-17) 0.8719 
Male, # (%) 15/22 (68.2) 7/13 (53.8) 0.4803 
Signs and Symptoms, # (%)  
• Insidious onset 
• Acute hepatitis 
• Acute liver failure 
• Complications of cirrhosis 
 
13/22 (59.1) 
8/22 (36.4) 
0/22 (0) 
1/22 (4.5) 
 
8/13 (61.5) 
3/13 (23.1) 
0/13 (0) 
2/13 (15.4) 
 
1.0000 
0.4776 
1.0000 
0.5412 
Associated IBD, # (%) 
• UC 
• CD 
• Unclassified IBD 
20/22 (90.9) 
18/22 (81.8) 
2/22 (9.1) 
0/22 (0) 
6/13 (46.1) 
6/13 (46.1) 
0/13 (0) 
0/13 (0) 
0.0060* 
0.0571 
0.5193 
1.0000 
Associated autoimmune disorders, # (%) 3/22 (13.6) 3/13 (23.1) 0.6485 
Cirrhosis, # (%) 2/22 (9.1) 2/13 (15.8) 0.6176 
 
PSC: primary sclerosing cholangitis; PSC/AIH: primary sclerosing cholangitis/autoimmune hepatitis 
overlap syndrome; IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease. 
Fisher’s Exact Test for categorical variables and Mann-Whitney Test for continuous variables. *p 
significant when < 0.05. 
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Table 3. Histologic features on the liver biopsy at the time of diagnosis of PSC and 
PSC/AIH in paediatric patients after the reassessment of the disease.  
 PSC 
n=12 
PSC/AIH 
n=13 
Grading (inflammation) # (%)   
0 9/12 (75) 2/13 (15) 
1 3/12 (25) 2/13 (15) 
2 0/12 (0) 4/13 (31) 
3 0/12 (0) 5/13 (39) 
Staging (fibrosis) # (%)   
0 4/12 (33) 3/13 (23) 
1 3/12 (25) 3/13 (23) 
2 2/12 (17) 3/13 (23) 
3 2/12 (17) 2/13 (15) 
4 1/12 (8) 2/13 (15) 
PSC changes # (%)   
0 6/12 (50) 9/13 (69) 
1 1/12 (8) 1/13 (8) 
2 3/12 (25) 1/13 (8) 
3 2/12 (17) 2/13 (15) 
Interface hepatitis # (%)   
0 9/12 (75) 0/13 (0) 
1 3/12 (25) 4/13 (31) 
2 0/12 (0) 5/13 (38) 
3 0/12 (0) 4/13 (31) 
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PSC: primary sclerosing cholangitis; PSC/AIH: primary sclerosing cholangitis/autoimmune hepatitis 
overlap syndrome.  
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Table 4.  The biochemical and serological parameters at the time of diagnosis of PSC or 
PSC/AIH in paediatric patients 
 PSC 
n=22 
PSC/AIH 
n=13 
p 
Biochemical parameters    
• AST median (range) IU/L 114 (24-483) 
n=22§ 
219 (30-1385) 
n=12§ 
 0.1335 
• ALT median (range) IU/L 253 (14-702) 
n=22§ 
413 (88-2276) 
n=12§ 
0.0999 
• GGT median (range) IU/L 257 (10-577) 
n=22§ 
178 (16-1089) 
n=12§ 
0.8137 
• ALP ° 14/22 (63.6) 
n=22§ 
8/12 (66.7) 
n=12§ 
1.0000 
• Bilirubin median (range) mcmol/L 10 (5-45) 
n=22§ 
18.5 (6-169) 
n=12§ 
0.0430* 
• Albumin median (range) g/L 41.4 (29-46) 
n=22§ 
35.7 (28.7-43) 
n=12§ 
0.0110* 
• INR median (range) 1.1 (1.0-1.3) 
n=21§ 
1.1 (0.9-1.6) 
n=11§ 
0.7051 
Serological parameters    
• IgG median (range) g/L 18.3 (9.1-27.6) 
n=22§ 
22.8 (9.2-88.8) 
n=11§ 
0.0352* 
• IgM median (range) g/L 1.2 (0.6-2.6) 
n=22§ 
1.4 (0.4-2.0) 
n=10§ 
0.8338 
• ANA and/or SMA (%) 5/22 (22.7) 
n=22§ 
8/12 (66.7) 
n=12§ 
0.0248* 
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• ANCA (%) 8/14 (57.1) 
n=14§ 
7/9 (77.8) 
n=9§ 
0.3998 
PSC: primary sclerosing cholangitis; PSC/AIH: primary sclerosing cholangitis/autoimmune hepatitis 
overlap syndrome; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma 
glutamyltranspeptidase; ALP: alkaline phosphatase; INR: international normalized ratio; IgM: 
immunoglobulin M; IgG: immunoglobulin G; ANA: antinuclear antibody; SMA: anti-smooth muscle 
antibode; anti-LKM1: antibody to the liver/kidney microsome type 1; pANCA: perinuclear 
antineutrophil cytoplasmic antibody.  
§ number of patients tested. Continuous variables are expressed as median and range (in brackets), 
categorical variables like number and percentage (in brackets). °Rate of patient with ALP over the 
upper limit. Fisher’s Exact Test for categorical variables and Mann-Whitney Test for continuous 
variables. *p significant when < 0.05. 
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Figure 1. Transaminase and GGT level in paediatric onset PSC patients at the time of 
diagnosis (1) and at the last follow-up (2) 
 
PSC: primary sclerosing cholangitis; ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; GGT: gamma glutamyltranspeptidase.  
On y-axis liver tests at the time of diagnosis (1) and in the last follow-up (2) are reported. On x-axis 
the median value and range of liver tests expressed in IU/L are reported. Liver tests at the time of 
diagnosis and in the last follow-up were compared by Wilcoxon Test. *p significant when < 0.05. 
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Figure 2. Transaminase and GGT level in PSC/AIH patients with paediatric onset at the 
time of diagnosis (1) and in the last follow-up (2) 
 
PSC/AIH: primary sclerosing cholangitis/autoimmune hepatitis overlap syndrome; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamyltranspeptidase.  
On y-axis liver tests at the time of diagnosis (1) and in the last follow-up (2) are reported. On x-axis 
the median value and range of liver tests expressed in IU/L are reported. Liver tests at the time of 
diagnosis and in the last follow-up were compared by Wilcoxon Test. *p significant when < 0.05. 
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Figure 3. Long-term outcome of PSC and PSC/AIH patients 
 
 
 
 
 
PSC: primary sclerosing cholangitis; PSC/AIH: primary sclerosing cholangitis/autoimmune hepatitis 
overlap syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median follow-up (range): 8 years (2-20) 
ALL 35 PTS ALIVE 
No liver transplantation  
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Figure 4. Kaplan-Meier curves showing transplant free survival in patients with PSC 
and PSC/AIH. 
 
 
 
 
 
PSC: primary sclerosing cholangitis; PSC/AIH: primary sclerosing cholangitis/autoimmune hepatitis 
overlap syndrome.  
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